Furmonertinib rechallenge after almonertinib-induced interstitial lung disease in EGFR-mutant advanced lung adenocarcinoma: a case report

Background EGFR tyrosine kinase inhibitors (EGFR-TKIs) are effective treatments for EGFR-mutant advanced non-small cell lung cancer, but drug-induced interstitial lung disease (ILD) can interrupt treatment. Resuming EGFR inhibition after ILD presents a difficult decision when chemotherapy is poorly tolerated. Case presentation A 69-year-old woman with stage IVB lung adenocarcinoma harboring an EGFR exon 21 L858R mutation and EGFR amplification discontinued chemotherapy after one cycle because of gastrointestinal intolerance. Almonertinib produced a partial response in the primary lung lesion and brain metastases. After approximately 3 months, she developed cough, chest tightness, hypoxemia, and bilateral pulmonary infiltrates. Evaluation for infection, autoimmune disease, cardiac dysfunction, and tumor progression supported almonertinib-induced ILD. Bronchoalveolar lavage showed 89.0% lymphocytes, with negative pathogen testing. Almonertinib was discontinued, and systemic corticosteroids led to clinical and radiological improvement. Following multidisciplinary review and informed consent, furmonertinib 80 mg once daily was started on November 15, 2025, while she was taking oral methylprednisolone 16 mg daily. The methylprednisolone dose was gradually tapered. Corticosteroids were discontinued on February 15, 2026. At the last follow-up on April 18, 2026, approximately 5 months after initiation of furmonertinib, systemic and intracranial disease remained controlled, with no recurrence or worsening of ILD. Conclusion This case documents resumption of EGFR inhibition with an alternative third-generation EGFR-TKI after improvement of almonertinib-induced ILD. Clinical and radiological recovery, prior tumor response, available treatment alternatives, patient preference, and close monitoring informed the decision.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1932940
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Furmonertinib rechallenge after almonertinib-induced interstitial lung disease in EGFR-mutant advanced lung adenocarcinoma: a case report

张丽沙, Qingsen Gao, Jia Wang, Dongxing Yang et al.
5 links
Frontiers in Oncology
Lung Cancer Treatments and Mutations
article

Furmonertinib rechallenge after almonertinib-induced interstitial lung disease in EGFR-mutant advanced lung adenocarcinoma: a case report

张丽沙, Qingsen Gao, Jia Wang, Dongxing Yang, Chenxi Wei
article en

Abstract

Background EGFR tyrosine kinase inhibitors (EGFR-TKIs) are effective treatments for EGFR-mutant advanced non-small cell lung cancer, but drug-induced interstitial lung disease (ILD) can interrupt treatment. Resuming EGFR inhibition after ILD presents a difficult decision when chemotherapy is poorly tolerated. Case presentation A 69-year-old woman with stage IVB lung adenocarcinoma harboring an EGFR exon 21 L858R mutation and EGFR amplification discontinued chemotherapy after one cycle because of gastrointestinal intolerance. Almonertinib produced a partial response in the primary lung lesion and brain metastases. After approximately 3 months, she developed cough, chest tightness, hypoxemia, and bilateral pulmonary infiltrates. Evaluation for infection, autoimmune disease, cardiac dysfunction, and tumor progression supported almonertinib-induced ILD. Bronchoalveolar lavage showed 89.0% lymphocytes, with negative pathogen testing. Almonertinib was discontinued, and systemic corticosteroids led to clinical and radiological improvement. Following multidisciplinary review and informed consent, furmonertinib 80 mg once daily was started on November 15, 2025, while she was taking oral methylprednisolone 16 mg daily. The methylprednisolone dose was gradually tapered. Corticosteroids were discontinued on February 15, 2026. At the last follow-up on April 18, 2026, approximately 5 months after initiation of furmonertinib, systemic and intracranial disease remained controlled, with no recurrence or worsening of ILD. Conclusion This case documents resumption of EGFR inhibition with an alternative third-generation EGFR-TKI after improvement of almonertinib-induced ILD. Clinical and radiological recovery, prior tumor response, available treatment alternatives, patient preference, and close monitoring informed the decision.

Frontiers in OncologyVol. 16
The Fourth People's Hospital of Zibo City (CN)
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon